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Summary Two P388 cell lines with acquired resistance to daunorubicin have been shown to exhibit cross-
resistance to anthrapyrazolone (NSC 357885). The degree of cross-resistance observed in these cell lines (58
and 150 fold) is similar to those observed towards daunorubicin (34 and 142 fold). However the decreased
drug accumulation observed for daunorubicin in the resistant cell lines (4-6 fold) is not observed for
anthrapyrazolone. Similarly, verapamil can increase daunorubicin accumulation in resistant cells but has no
effect on anthrapyrazolone accumulation. It is concluded that in contrast to daunorubicin, decreased
anthrapyrazolone accumulation is not the resistance mechanism operative in daunorubicin resistant cell lines
towards anthrapyrazolone.
The anthrapyrazole class of intercalating agents has been
shown to be effective against a variety of murine tumours
(Showalter et al., 1984a). These agents have been developed
in an attempt to overcome the cardiotoxicity associated with
the anthracycline antibiotics (Showalter et al., 1984b;
Leopold et al., 1984) which is believed to arise due to free
radical production following reduction of the anthracycline
to a semiquinone radical. The anthra[1,9-cd] pyrazol-6(2H)-
ones (anthrapyrazoles), in which the pyrazole ring is fused to
the anthracene chromophore, are much less readily reduced
compared with adriamycin. This may result in decreased free
radical production.
In this study two P388 cell lines with acquired resistance
to daunorubicin are shown to exhibit cross resistance to
anthrapyrazolone. The decreased cellular retention of drug,
observed in resistant cells on daunorubicin treatment, is not
seen with anthrapyrazolone.
Materials and methods
Chemicals
Anthrapyrazolone (NSC 357885, PD 113785, CI-941) was
kindly donated by the Warner-Lambert Co., Ann Arbor,
Michigan, USA. Verapamil was obtained from the Sigma
Chemical Co., Poole, Dorset, UK, and daunorubicin from
May and Baker Co., Dagenham, UK.
Cell culture
Two cell lines, showing decreased sensitivity to daunorubicin
(P388 R8/13 and P388 R8/22) were developed from the
parental P388 cell line by incremental challenge with the
drug in vitro. Cells were routinely grown in RPMI medium
supplemented with 10% horse serum (Gibco, UK) and were
regularly screened and shown to be mycoplasma free. Prior
to all experiments cells were counted (Coulter Counter) and
their viability checked by trypan blue exclusion. Growth
inhibition studies were carried out by back extrapolation of
growth curves obtained over ten days following a h
treatment of cells with drug. All experiments were performed
in triplicate.
Measurement ofdrug accumulation
Cells in exponential growth were centrifuged (800g, 10min,
4°C), washed with saline, and the cell pellet resuspended in
serum-free medium (RPMI 1640, Gibco, UK). Drugs were
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added to the concentrations required, and the cells incubated
at 37°C. Aliquots were removed at the times indicated in the
text, the cells were again centrifuged (1 500g, 5min, 4°C), the
cell pellets washed in phosphate buffered saline, resuspended
in lysis solution (0.1 M acetic acid) prior to sonication (MSE
20,um peak to peak, 20sec). Insoluble cell debris was
removed by centrifugation and the sonication-extraction
process repeated. Two successive extractions were found to
be sufficient to remove all soluble material. The supernatants
were combined and drug concentration determined spectro-
photometrically (Beckman DU8) at 490nm. No drug was
detectable in the phosphate buffered saline used to wash the
cell pellets. Similarly, no optical absorption was found in
untreated cells. For combinations of daunorubicin and
anthrapyrazolone absorptions at 460 and 530 nm were
determined. These allowed the determination of individual
drug concentrations within the mixture. The calculations
were performed on a BBC microcomputer, using the
extinction coefficients shown in Table I. This computation
was accurate to within 3% when applied to artificially mixed
drug solutions. All determinations were performed in
triplicate.
Flow cytofluorimetric determination of daunorubicin
content was determined directly by flow cytometry as
described previously (McGown et al., 1983). Excitation was
by the 488 nm line of an argon ion laser, and fluorescence
emission monitored at 540+20 nm. This method was
previously shown to be in good agreement with classical
drug extraction procedures.
Results
It can be seen from the growth inhibition data (Table II)
that the daunorubicin resistant cell lines show a high level
of cross-resistance to anthrapyrazolone. The cellular
accumulation of anthrapyrazolone in the parental (P388) and
resistant (P388 R8/13) cell lines as a function of time is
shown in Figure 1. It can be seen that both cell lines
incorporate the drug to the same level. Repetition of this
experiment showed no statistical difference in anthrapyra-
zolone accumulation (Students t test) between these cell lines.
Table I Extinction coefficients of daunorubicin
and anthrapyrazolone in 0.1 M acetic 1 mol-1 cm 1
E e
Drug 460nm 530nm
daunorubicin 6730 4620
anthrapyrazolone 14700 966
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Table II Growth inhibition (ID50) of cell lines treated with
daunorubicin or anthrapyrazolone (1 h)
ID50P388 ID5OP388R8113 ID50P388R8/22
daunorubicin 19nM 650nM 2.7pM
anthrapyrazolone 12nM 700nM 1.8pM
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Figure 2 Effect ofincreasing concentrations ofanthrapyrazolone
in the presence of daunorubicin (1Opm) on the cellular accumu-
lation of both drugs. Curve 1, intracellular daunorubicin, in P388
cells, curve 2 daunorubicin in P388 R8/13 cells, curve 3 anthra-
pyrazolone in P388 cells, and curve 4 anthrapyrazolone in
P388 R8/13 cells. Exposure time was for 2h and the intracellular
concentrations were measured by extraction procedures described
in Materials and methods.
Time (hours)
Figure 1 Cellular accumulation of anthrapyrazolone in P388
(x) and P388 R8/13) (0) cell lines.
The effect of simultaneous incubation of verapamil (10 uM)
on the uptake of either daunorubicin or anthrapyrazolone is
shown in Table III. It can be seen that verapamil causes a
considerable increase in the accumulation of daunorubicin in
the resistant cell lines, but shows little (or no) effect on the
parental P388 cell line. In contrast, verapamil addition has
no comparable selective effect on anthrapyrazolone
accumulation in the resistant cell lines. Following verapamil
treatment, anthrapyrazolone incorporation is increased to a
much lower extent than daunorubicin in the resistant cell
lines. In contrast to daunorubicin, verapamil does not
modify the relative uptake of anthrapyrazolone between the
parental and resistant sublines. The small increase in anthra-
pyrazolone incorporation observed in these cell lines (10-
20%) was however statistically significant (P<0.05, Students
t test).
The effects of simultaneous incubation of anthrapyra-
zolone and daunorubicin on drug accumulation in the P388
and P388 R8/13 cell lines are shown in Figures 2 and 3. The
effect of increasing the concentration of anthrapyrazolone
(0-20pM) in the presence of 10pM daunorubicin (Figure 2)
shows no effect on daunorubicin accumulation in either the
P388 or P388 R8/13 cell line. The effect of increasing
concentrations of daunorubicin in the presence of anthra-
pyrazolone (1O0m) (Figure 3) shows a concentration-
dependant increase in daunorubicin incorporation, with
higher levels of daunorubicin taken up by the parental cell
line. Little effect is seen on anthrapyrazolone accumulation
in either cell line.
Similarly no increase in daunorubicin accumulation on co-
incubation with anthrapyrazolone was observed using a flow
cytofluorimetric determination of intracellular daunorubicin
concentration (Table IV). The decrease in fluorescence
observed on anthrapyrazolone incubation is due to the
overlap of aborption spectra at the excition wavelength used
in this study.
Table II Effect of verapamil (10uM) on daunorubicin and
anthrapyrazolone accumulation (10pM, 370C, 2h) in P388, P388
R8/13, and P388 R8/22 cell lines. All intracellular drug levels are
expressed relative to drug accumulation in the absence of verapamil
(100%)
Relative drug incorporation (%)+s.d.
Drug P388 P388 R8/13 P388 R8/22
daunorubicin 102.3 (1.8) 423 (30) 573 (23)
anthrapyrazolone 117.7(11.4) 120.6 (10.2) 113.3 (10.3)
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Figure 3 Effect of increasing concentrations of daunorubicin in
the presence of anthrapyrazolone (10pm) on the cellular
accumulation of both drugs. Curve 1, daunorubicin in P388 cells,
curve 2, daunorubicin in P388 R8/13 cells, curve 3
anthrapyrazolone in P388 cells, and curve 4 anthrapyrazolone in
P388 R8/13 cells. Exposure time was for 2h and the intracellular
concentrations were measured by extraction procedures described
in Materials and methods.
Table IV Effect of anthrapyrazolone on daunorubicin
accumulation, measured by flow cytometry (±s.d.)
Fluorescence (arbitrary units)
Treatment P388 P388R8/13 P388R8122
DnR (1OpM) 68.7 (1.2) 14.3 (0.6) 21.3 (0.6)
DnR (10/pM)+ANTHRA (10pM) 55.3 (0.6) 14.6 (0.6) 17.0 (0)
DnR (l0pM)+ANTHRA (20ptM) 41.3 (0.6) 11.3 (0.6) 13.0 (0)
Discussion
The novel agent anthrapyrazolone (7-hydroxy-2-[(2-
hydroxyethyl) amino ethyl]-5-[[2-[(2-hydroxyethyl) amino]
ethyl] amino-anthra[l,9-cd]pyrazol-6-(2H)-one, NSC 357885)
is currently entering clinical trial under the Cancer Research
Campaign Phase I/II subcommittee scheme. The presence of
the pyrazolone ring attached to the anthracene chromophore
alters the reduction potential which reduces the likelihood of
production of free radical species, which have been
implicated in thc mechanism of cardiotoxicity.
(E(Q/Q- )=-538 mV for anthrapyrazolone and -328 mV
for adriamycin. J. Butler, pers. comm.) This drug has been
shown to be active against a variety of murine tumours
including L1210 and P388. Its mode of action is likely to be
due to intercalation of the planar ring system into the DNA
helix, with subsequent inhibition of DNA-directed cellular
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processes (Showalter et al., 1984b; Leopold et al., 1984; Fry
et al., 1984).
The phenomenon of cross-resistance between a wide
variety of structurally diverse agents (e.g. the anthracyclines,
vinca alkaloids, actinomycin D, mitoxantrone and menogarol)
has already been widely reported (Tsuruo et al., 1985; Dano,
1972). Resistance to these agents is associated with increased
efflux of drug from cells (McGown et al., 1983; Dano et al.,
1983). The mechanism by which drug is excluded from
resistant cells is not known but it has been shown to be
energy dependant, and can be inhibited by some calcium
channel blockers such as verapamil (Tsuruo et al., 1985;
Dano et al., 1983).
The novel agent anthrapyrazolone shows a high level of
cross-resistance to two cell lines with acquired resistance to
daunorubicin. The structural similarity of this agent to the
anthracyclines, and the structural diversity found in the
agents involved in the multi-drug resistance phenomenon
(Tsuruo et al., 1985; Dano, 1972; McGown et al., 1983;
Dano et al., 1983) makes this observed cross-resistance
predictable. However the lack of differential accumulation of
anthrapyrazolone between the parental and resistant cell
lines is contrary to the expected result. The lack of any effect
of verapamil in increasing the amount of anthrapyrazolone
in the resistant cell lines is also evidence that drug efflux is
not the important resistance mechanism towards this drug in
our cell line. In the case of daunorubicin the drug level
within the resistant cells can be increased to that observed in
the parental cells. Further evidence against increased drug
efflux as the mechanism of resistance towards anthrapyra-
zolone is shown in Figures 2 and 3. It can be seen that the
drug accumulation in the resistant cells is not affected by co-
incubation with combinatidns of daunorubicin and anthra-
pyrazolone, hence it is unlikely that these agents share the
same drug efflux mechanism which is believed to be involved
in pleotropic drug resistance.
These data suggest that resistance to anthrapyrazolone in
these cell lines is not due to decreased drug retention.
Resistance to daunorubicin is, however, associated with
decreased drug retention. This leads to the conclusion that
while decreased drug concentration within the cell may be a
contributory factor to drug resistance other, perhaps more
important processes, must also be operating within these
resistant cells. This is in agreement with Capranico et al.
(1986a,b) who have shown differential DNA damage in
sensitive and doxorubicin-resistant P388 cell lines, which is
independent of membrane changes. Klohs et al. (1986)
showed, for a series of anthrapyrazolone derivatives (not
including the one used in this study), that subtle changes in
substitution on the anthrapyrazole moeity resulted in a large
change in the degree of cross-resistance to an adriamycin-
resistant cell line. A number of calcium channel blockers and
calmodulin antagonists including verapamil were shown to
vary considerably in their effect on 72h growth inhibition in
the presence of the anthracyclines and anthrapyrazolone
derivatives. However no data was presented on the
accumulation of the anthrapyrazole derivatives in the cell
lines tested.
In conclusion, resistance to daunorubicin is associated
with decreased intracellular drug levels, whereas the
resistance mechanism operating towards anthrapyrazolone
(NSC 357885) is not due to altered drug transport. The
implications of this towards resistance to daunorubicin have
yet to be elucidated.
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